Adimab LLC, a provider of therapeutic antibody discovery and engineering technologies, said on Wednesday that it congratulates biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) for recently receiving approvals from the European Commission and China's National Medical Products Administration (NMPA) for depemokimab.

This adds to recent marketing approvals in the United States, Japan, and the United Kingdom. Depemokimab is the first ultra-long-acting biologic product approved for use in its indicated conditions and was developed internally by GSK with an extended half-life and engineered high binding affinity to enable twice-yearly dosing, as demonstrated in GSK's pivotal trials.

To support in the engineering of the molecule, GSK internalised Adimab's proprietary yeast-based technology, enabling in-house antibody discovery, optimisation, production, and characterisation on any target of GSK's choosing. GSK's research team used the Adimab Platform for depemokimab, a product tailored to meet GSK's target product profile, including low picomolar affinity. According to Adimab, GSK continues to use the Adimab platform to support other internal programmes.

Adimab's other Platform Transfer collaborators include Biogen, Lilly, Merck, Novo Nordisk, and Takeda.